Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 26 studies | 31% ± 15% | |
B cell | 25 studies | 33% ± 14% | |
conventional dendritic cell | 24 studies | 43% ± 16% | |
dendritic cell | 21 studies | 44% ± 18% | |
plasmacytoid dendritic cell | 15 studies | 31% ± 11% | |
naive B cell | 14 studies | 34% ± 10% | |
memory B cell | 13 studies | 28% ± 9% | |
monocyte | 11 studies | 29% ± 11% | |
non-classical monocyte | 9 studies | 27% ± 7% | |
classical monocyte | 7 studies | 20% ± 3% | |
myeloid cell | 7 studies | 37% ± 9% | |
CD8-positive, alpha-beta T cell | 6 studies | 21% ± 6% | |
monocyte-derived dendritic cell | 4 studies | 50% ± 28% | |
leukocyte | 4 studies | 27% ± 9% | |
alveolar macrophage | 3 studies | 32% ± 7% | |
microglial cell | 3 studies | 26% ± 5% | |
capillary endothelial cell | 3 studies | 23% ± 9% | |
intermediate monocyte | 3 studies | 51% ± 18% | |
mononuclear phagocyte | 3 studies | 42% ± 12% |
Insufficient scRNA-seq data for expression of HLA-DQA2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 89% | 1387.54 | 512 / 578 | 75% | 96.03 | 865 / 1155 |
breast | 74% | 469.61 | 339 / 459 | 74% | 68.93 | 830 / 1118 |
kidney | 66% | 341.56 | 59 / 89 | 67% | 87.85 | 601 / 901 |
skin | 68% | 378.42 | 1224 / 1809 | 63% | 84.23 | 297 / 472 |
thymus | 57% | 257.27 | 371 / 653 | 69% | 70.36 | 416 / 605 |
uterus | 48% | 163.56 | 82 / 170 | 61% | 60.20 | 281 / 459 |
prostate | 58% | 182.75 | 143 / 245 | 51% | 20.57 | 254 / 502 |
intestine | 58% | 312.81 | 564 / 966 | 45% | 26.74 | 235 / 527 |
bladder | 52% | 195.33 | 11 / 21 | 50% | 42.87 | 252 / 504 |
esophagus | 54% | 150.17 | 784 / 1445 | 44% | 24.91 | 81 / 183 |
lymph node | 0% | 0 | 0 / 0 | 97% | 327.30 | 28 / 29 |
spleen | 89% | 1748.30 | 214 / 241 | 0% | 0 | 0 / 0 |
stomach | 39% | 133.56 | 141 / 359 | 49% | 35.02 | 140 / 286 |
tonsil | 0% | 0 | 0 / 0 | 82% | 92.11 | 37 / 45 |
pancreas | 15% | 31.38 | 48 / 328 | 67% | 59.48 | 119 / 178 |
adrenal gland | 50% | 279.81 | 130 / 258 | 30% | 10.21 | 68 / 230 |
adipose | 73% | 544.58 | 873 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 71% | 2099.48 | 663 / 929 | 0% | 0 | 0 / 0 |
ovary | 18% | 46.88 | 33 / 180 | 49% | 41.74 | 212 / 430 |
liver | 23% | 43.45 | 51 / 226 | 43% | 22.94 | 175 / 406 |
blood vessel | 63% | 316.14 | 840 / 1335 | 0% | 0 | 0 / 0 |
brain | 17% | 50.70 | 455 / 2642 | 30% | 20.32 | 211 / 705 |
heart | 33% | 69.68 | 288 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 17.08 | 20 / 80 |
muscle | 19% | 34.04 | 152 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050870 | Biological process | positive regulation of T cell activation |
GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0031902 | Cellular component | late endosome membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0032588 | Cellular component | trans-Golgi network membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
GO_0042613 | Cellular component | MHC class II protein complex |
GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0023026 | Molecular function | MHC class II protein complex binding |
GO_0032395 | Molecular function | MHC class II receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0042605 | Molecular function | peptide antigen binding |
Gene name | HLA-DQA2 |
Protein name | HLA class II histocompatibility antigen, DQ alpha 2 chain (DX alpha chain) (HLA class II histocompatibility antigen, DQ(6) alpha chain) (HLA-DQA1) (MHC class II DQA2) MHC class II antigen HLA class II histocompatibility antigen DQ alpha chain (HLA class II histocompatibility antigen, DQ alpha 2 chain) (MHC class II antigen) HLA class II histocompatibility antigen, DQ alpha 2 chain (HLADQA2) (MHC class II antigen) HLADQA2 (MHC class II antigen) HLADQA2 (MHC class II antigen) (Major histocompatibility complex, class II, DQ alpha 2) HLA-DQA2 protein |
Synonyms | HLA-DQA1 ICRF6c-DV19.1-001 HLA-DXA |
Description | FUNCTION: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. . |
Accessions | ENST00000453672.2 ENST00000446482.2 ENST00000449560.5 ENST00000443184.2 A0A140TA34 ENST00000241802.9 A0A1U9X7S6 P01906 A0A345F7D7 Q76NI6 Q30087 A0A1U9X7T6 ENST00000552745 ENST00000447735.5 ENST00000551533.1 ENST00000546801.2 ENST00000415898.2 Q29995 A0A1U9X7T4 Q5Y7D2 A0A345F7E0 ENST00000547960.2 A0A1U9X7T9 ENST00000374940.4 |